MedTrace Logo

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

NCT05596526 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-04-10

No results posted yet for this study

Summary

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

Conditions

  • Shingles
  • Zoster

Interventions

BIOLOGICAL

recombinant zoster vaccine

Shingrix® vaccine will be administered in two vaccinations on Day0 and Day60

Sponsors & Collaborators

  • Prof Patrice Lalive

    lead OTHER

Principal Investigators

  • Patrice Lalive, Pr · University Hospitals of Geneva

  • Arnaud Didierlaurent, Pr · University Hospitals of Geneva

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05596526 on ClinicalTrials.gov